Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study

Johnson & Johnson JNJ on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate response to standard therapies.

The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks compared to placebo.

In the Phase 3b APEX study, Tremfya-treated patients also exhibited significantly less progression of structural damage versus patients receiving a placebo at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score, which includes joint space narrowing and erosion subscores.

Also Read: US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims

Data were consistent with the well-established safety profile of Tremfya with no new safety signals identified.

APEX is a Phase 3b study with long-term extension data through three years that will further assess the sustained efficacy of Tremfya on inhibition of structural damage in patients with active PsA.

Results from the APEX study are being prepared for presentation at upcoming medical congresses.

Johnson & Johnson Stock Prediction For 2025

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Johnson & Johnson, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Johnson & Johnson, the 200-day moving average sits at $156.5, according to Benzinga Pro, which is above the current price of $155.82. For more on charts and trend lines, see a description here.

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

Price Action: JNJ stock is down 3.51% at $154.21 at the last check Friday.

Read Next:

• Matador Resources Sells Eagle Ford Assets, Announces Potential Buybacks

Photo by Tada Images via Shutterstock